Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Non-Current Liabilities data on file, last reported at $423.7 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 37.07% year-over-year to $423.7 million in Q1 2026; TTM through Mar 2026 was $423.7 million, a 37.07% increase from a year earlier, with the FY2025 full-year figure at $368.7 million, up 10.95% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $423.7 million, up from $368.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for SUPN reached as high as $841.6 million in Q2 2022 and fell as low as $309.1 million in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $486.6 million across 5 years, with a median of $368.0 million in 2024.
• Across the five-year window, Total Non-Current Liabilities slumped 61.55% in 2023 and surged 37.07% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $807.6 million in 2022, then tumbled by 56.7% to $349.7 million in 2023, then dropped by 4.97% to $332.3 million in 2024, then climbed by 10.95% to $368.7 million in 2025, then climbed by 14.91% to $423.7 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $423.7 million in Q1 2026, $368.7 million in Q4 2025, and $369.9 million in Q3 2025.